AUS
NZ
UK
CA
USA
IND
_06_16_2026_05_20_09_929099.jpg)
As CommonWealth Bank (ASX:CBA) was getting thrashed down by the Slater &Gordon for fees gouging and paying below standard market rate, Hayne Royal Commission spotted a litany of delays and denials in its insurance claims. On Wednesday, Royal Commission into Misconduct in the Banking, Superannuation and Financial Services Industry highlighted several dodgy practices undertaken by insurers. Among all, CommonWealth Bankâs insurance arm was on the top of collision course with the public.
The counsel assisting the commission, Rowena Orr, QC, took CommInsure's managing director Helen Troup through events that included the denial of claims to the policy holder on not meeting the definition of heart attack and thereafter misleading the Financial Ombudsman Service. [optin-monster-shortcode id="wxhmli4jjedneglg1trq"]
In January 2014, CommInsure declined a womanâs trauma cover claim for breast cancer stating she did not have mastectomy. That was because the readings of policy holderâs troponin which is used to diagnose a heart attack was below the readings required to claim heart attack according to CommInsureâs backdated policy. At a conciliation, CommInsure tried to settle the dispute by offering half the insured sum but customer declined the settlement offer.
The denials of claims to the heart attack sufferer comes after the insurer has decided not to update the medical definition for heart attack. The world heart federation updated the global definition for heart attack in 2007 but CommonWealth Bank did not update its definition until 2016. This must have helped the company to save around $2.5 million but now it brings it in disputes with policy holders and other regulatory bodies.
Following this disclosure, CommonWealth Bankâs share price slipped by 0.966% to $71.235 on 13 September 2018 (1:04 PM AEST). The stock has seen a performance change of -5.26% over the past one year.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a companyâs prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkineâs team of analysts bought you handpicked report for âTop 25 Dividend Stocks For 2018.â
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
